In order to prove that, future mulitvariant analysis will be required to evaluate IL-33 mRNA/protein expression levels with clinicopathological variables which are currently used as important diagnostic features in prostate cancer, such as stage of disease, PSA level, and Gleason Score. This evidence concerns the gene IL33 and Familial prostate cancer.